Inspire Medical Systems Inc

Inspire Medical Systems is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA). The company's proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology for moderate to severe OSA, offering a closed-loop sensing system that delivers electrical stimulation to the hypoglossal nerve to maintain airway patency during sleep. The Inspire system consists of an implantable neurostimulator, a stimulation lead, and a patient remote control. The company's latest-generation Inspire V system features improved sensing capabilities, 3T MRI compatibility, reduced surgical implant time, SleepSync digital health connectivity, and an average battery life of 11 years. Inspire serves over 140,000 implanted patients through more than 1,500 implanters, targeting a domestic market opportunity estimated at over $10 billion with less than 5% penetration. The company generates revenue from device sales primarily in the United States, with growing international presence across Europe and Asia Pacific markets including Japan, Singapore, and the United Kingdom. Inspire holds 119 issued U.S. patents and 83 issued foreign patents, and operates under a royalty-free perpetual license agreement with Medtronic for upper airway electrical stimulation technology. Updated Aug 3, 2026